Through Integration of Pharmacology And Clinical Know-How
CRC - Centro Ricerche Cliniche di Verona
The Centro Ricerche Cliniche di Verona (CRC) was founded in 2005 and is located in the G.B. Rossi General Hospital. It is owned and operated by The Verona University Hospital and Verona University.
Our mission is to assist both commercial and non-profit research organizations in early clinical drug development. The objectives of the CRC are to:
Conduct Phase I and Proof-of-Concept clinical trials to the highest standards of quality and with rapid turn-around;
Support the development of interdisciplinary scientific collaboration;
Share facilities and know-how with private or public organizations involved in pharmacological research;
The CRC specialises in designing and executing Proof-of-Concept studies using targeted populations, state-of-the-art technology and human disease.
A full range of Clinical Pharmacology services is also provided (e.g. single/multiple ascending dose, drug-drug interaction, pharmacokinetics, food effects, bioequivalence) by means of an in-house Clinical Pharmacology Unit, equipped to the highest standards and operating in close connection with specialist intensive care expertise in Cardiology, Anaesthesiology, Internal Medicine, Surgery and Neurology.
The CRC is in full compliance with International Good Clinical Practice (GCP) standards and is Certified according to the UNI EN ISO 9001:2008 standard; transition to the 9001:2015 ISO standard has been completed in 2018.
The CRC Quality Management System (QMS) comprises our mechanisms for ensuring that all our services are performed to the highest ethical standards, conform to all regulatory requirements and satisfies contractual obligations.
We continually improve the effectiveness of its QMS through a systematic approach, starting from defining and planning strategy and objectives in order to standardize implementation and compliance by a defined Quality Policy and procedures, checking effectiveness and compliance by QA, QC, Management Review, data and project review, audits and customer survey results.
Il CRC necessita di n. 1 Regulatory Specialist in supporto alle attività di ricerca
finalizzate allo sviluppo di nuove terapie.
L’assunzione avrà le seguenti caratteristiche:
Tipologia: Borsa di studio;
Durata: 10 (dieci) mesi;
Orario di lavoro: tempo pieno per un numero di ore settimanali pari a 40
(quaranta).
Per conoscere i requisiti e le competenze, potete consultare il bando di selezione e la domanda, disponibili a questo link:
Bando per Borsa di studio e domanda
Se sei interessato/a invia il tuo CV a info@crc.vr.it entro le 17,30
di venerdì 26 maggio 2023.
27/04/2023
STIAMO CERCANDO
volontari sani, tra i 18 e i 60 anni. Non fumatori, vaccinati per Covid19,
che non abbiano partecipato ad altri studi clinici negli ultimi 6 mesi per
una ricerca con farmaci anti-ipertensivi.
L’impegno consiste in:
Visita di screening;
Tampone naso-faringeo per SARS-Cov2 prima dei periodi di permanenza al CRC;
Periodo 1: permanenza al CRC per 3,5 giorni e poi tornerà per un prelievo al mattino per 2 volte;
Pausa di 2 settimane circa;
Periodo 2: uguale al periodo 1;
Visita di fine studio.
Per il tempo e l’impegno richiesti è prevista un’indennità adeguata.
Chiama il numero 045/8126615 dalle 9 alle 15 (fuori orario lascia un messaggio)
o scrivi una mail a volontari@crc.vr.it e chiedi dello studio ZOF_AMLO_02.
21/04/2023
Lavora con noi - Work with us
Il CRC necessita di assumere n.1 Supporto Amministrativo per le attività di gestione
amministrativa e finanziaria per la realizzazione di studi clinici.
L’assunzione avrà le seguenti caratteristiche:
Tipologia: apprendistato livello 4°;
Durata: 36 (trentasei) mesi;
Orario di lavoro: tempo pieno per un numero di ore settimanali pari a 40
(quaranta).
Per conoscere i requisiti e le competenze, potete consultare il bando di selezione e la domanda, disponibili a questo link:
Bando per Borsa di studio e domanda
Se sei interessato/a invia il tuo CV a info@crc.vr.it entro le 17,30
di venerdì 5 maggio 2023.
03/03/2023
STIAMO CERCANDO
volontari sani, maschi e femmine, iscritti al Servizio Sanitario Nazionale, di età tra i 18 e i 60 anni, NON FUMATORI o ex fumatori da almeno 3 mesi, normopeso, di etnia caucasica,
con accesso venoso sufficiente a consentire i prelievi di sangue, che non abbiano donato sangue negli ultimi 3 mesi
e che non abbiano partecipato ad altri studi clinici negli ultimi 6 mesi.
A ciascun partecipante sarà richiesto questo impegno di tempo:
Visita di screening di circa 3-4 ore (al mattino a digiuno).
4 periodi di studio, ciascuno di 2 notti e 1 giorno intero al CRC, con ritorno alla sera per un prelievo 12 ore dopo l’orario dell’uscita mattutina.
Il giorno dell’entrata di ciascun periodo lei dovrà fare un tampone antigenico per SARS-Cov2
Visita di fine studio (7 gg ±2 dopo l’ultimi periodo di studio)
Questo schema è previsto per 4 periodi in totale.
La forma farmaceutica è la compressa.
Per il tempo e l’impegno richiesti è prevista un’indennità adeguata.
Dr Milleri, Scientific Medical Director of the Centro Ricerche Cliniche di Verona srl, is pleased to announce the publication of the article "A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19," which he co-authored.
...
The article was published in the journal Molecular Therapy, specialized in advanced genetic research, and sets out the results of the clinical study "PHASE I/II STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF COVID-eVAX, A PLASMID DNA VACCINE CANDIDATE FOR COVID-19 IN ADULT HEALTHY VOLUNTEERS". The study was carried out between February and December 2021 in four major Italian clinical research centers: the National Cancer Institute, IRCCS, Fondazione G. Pascale, Naples; the University Milano-Bicocca/Ospedale San Gerardo, Monza; INMI Lazzaro Spallanzani, Rome; and Centro Ricerche Cliniche di Verona srl - CRC.
The clinical trial was funded by Takis and Rottapharm Biotech, the two Italian companies that developed COVID-eVax, the first COVID-19 DNA platform-based vaccine to reach clinical development in Europe. The purpose of the study was to test whether the investigational vaccine could be safe and effective in preventing coronavirus (SARS-COV-2) infection, which can cause COVID-19 disease.
The COVID-eVax vaccine was administered with an intramuscular injection, into the upper arm (deltoid muscle) via an instrument equipped with 4 electrodes, which allow a procedure called "electroporation," that is, the application of an electric field that causes the vaccine to enter the cells.
The study found that COVID-eVax was well tolerated and induced an immune response (antibodies and/or T-binding cells) in up to 90% of healthy volunteers at the highest dose. However, the vaccine did not induce antibodies with activity capable of blocking the virus, while T-cell (lymphocyte) mediated immunity was particularly relevant. This T-cell-mediated immunological response adds significant information to the DNA vaccine platform and should be evaluated in further studies for its protective capacity and potential utility in other therapeutic areas, such as oncology. T cells could indeed act selectively against cancer cells.
Special thanks go to the healthy volunteers who participated in this study, foregoing the national vaccination campaign, to contribute to clinical research on anti-Covid19 vaccines.